FDA guidance explains presentation of risk information in US drug and device ads
This article was originally published in RAJ Devices
Executive Summary
The US Food and Drug Administration has explained in a draft guidance the factors it intends to consider when evaluating the advertisements and promotional labelling of prescription drugs and medical devices to ascertain whether they effectively communicate the product’s benefit and risk information1,2.